Liestal, Switzerland, October 19, 2011 - Santhera Pharmaceuticals (SIX: SANN) announced today that it will present data from the 2-year open-label study (DELPHI-E study) evaluating Catena® for the treatment of Duchenne Muscular Dystrophy , one of the most common and devastating types of muscular dystrophy. The findings indicate that Catena® slowed the decline in respiratory function compared to the expected natural history in patients with Duchenne Muscular Dystrophy. Data from this study are in agreement with and confirm data from a randomized controlled study (DELPHI study) of 12 months duration . The poster presentation will be given at the 16th International Congress of the World Muscle Society in Almancil, Portugal on October 21, 2011.
 Buyse G.M., Goemans N., van den Hauwe M., Thijs D., Wei Hui, Rummey C., Meier T., Mertens L.: Results from a two-year open label intervention study with idebenone (Catena®) in patients with Duchene Muscular Dystrophy. Poster presentation at the 16th International Congress of the World Muscle Society in Almancil, Portugal, from October 18 to 22, 2011.
 Buyse G.M., Goemans N., van den Hauwe M., Thijs D., de Groot I.J.M., Schara U., Ceulemans B., Meier T., Mertens M.: Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: Results from a 12 month, double-blind, randomized placebo-controlled trial. Neuromuscular Disorders 2011; 21:396-405.